N. Tarazona Llavero

LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Sara Lonardi, Filippo Pietrantonio, N. Tarazona Llavero et al. · Annals of Oncology · 2023 · 58 citations · Full text

Medicine, Oncology, Surgery +16

511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial

C. Santos Vivas, J. Vidal Barrull, C. Fernandez Rodriguez et al. · Annals of Oncology · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15

Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype

N. Tarazona Llavero, Francisco Gimeno-Valiente, Valentina Gambardella et al. · Annals of Oncology · 2019 · 12 citations

Medicine, Molecular Genetics, Oncology +17

723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial

S. Marsoni, Michele Prisciandaro, N. Tarazona Llavero et al. · Annals of Oncology · 2025 · 10 citations

Medicine, Oncology, Surgery +14